Antibody programs here are built on a Function-First approach that pulls functional screening, developability and risk assessment forward into the earliest discovery stages. The wet lab side runs target-informed immunization and B cell Select technology, which the company reports meets predefined discovery criteria in more than 98 percent of campaigns. On the computational side, LensAI, powered by HYFT technology, unifies biological data across sequence, structure, function and literature, and the newer ReefIQ data substrate adds a biological context layer for AI-driven design. Separate service lines cover therapeutic antibody discovery, anti-drug antibody discovery, diagnostic antibody discovery, and protein engineering and production, alongside LensAI offered as SaaS for teams that prefer to run analyses in house. The group cites more than 35 years of operating experience, contributions to over 20 client molecules that reached the clinic, and use by teams at 19 of the top 20 global pharmaceutical companies. It now operates as MindWalk, listed on NASDAQ as HYFT.
ImmunoPrecise
ImmunoPrecise Antibodies (IPA) is an advanced biotherapeutic research and technology company utilizing artificial intelligence, high-throughput screening, and multi-species antibody discovery platforms. IPA delivers full-service, end-to-end therapeutic antibody discovery and engineering solutions, assisting global pharmaceutical clients in moving from target identification to optimized, developable lead candidates.
